Posts

RQ Bio raises $115M to advance long‑acting flu prevention antibody into clinic

on

Helmed by Sanofi vet, Bionyra emerges with $165M and three licensed I&I assets

on

Migraine biotech makes its debut with $46M to advance preclinical pipeline

on

Celldex Reports Strong Retreatment Results With Barzolvolimab In Cold Urticaria and Symptomatic Dermographism

on

Eli Lilly Licenses CSL's Clazakizumab IL-6 Antibody for $100 Million

on

Sanofi and Teva's Duvakitug Demonstrates Durable Efficacy in Phase 2b Maintenance Study for Ulcerative Colitis and Crohn's Disease

on

Just – Evotec Biologics Receives Gates Foundation Grant for AI-Driven Optimization of Monoclonal Antibody Developability

on

Just – Evotec Biologics Receives Gates Foundation Grant for AI-Driven Optimization of Monoclonal Antibody Developability

on

Just – Evotec Biologics Receives Gates Foundation Grant for AI-Driven Optimization of Monoclonal Antibody Developability

on

Just – Evotec Biologics Receives Gates Foundation Grant for AI-Driven Optimization of Monoclonal Antibody Developability

on

Just – Evotec Biologics Receives Gates Foundation Grant for AI-Driven Optimization of Monoclonal Antibody Developability

on

mAbxience and HP Drive the Use of Artificial Intelligence in Biomanufacturing and Biosimilar Development

on

Otsuka's Anti-APRIL Antibody (Voyxact/Sibeprenlimab) Receives FDA Approval for IgA Nephropathy (IgAN)

on

Dupixent Gains EU Approval as First Targeted Therapy for Chronic Spontaneous Urticaria in Over a Decade

on

Ipsen to Acquire ImCheck Therapeutics for €350 Million to Expand Immunotherapy Pipeline

on

Allogene Reports Patient Death Linked to ALLO-647 Conditioning Antibody in CAR-T Trial

on

ACIP Backs Merck's Enflonsia for RSV Prevention in Infants

on

Invivyd Highlights Follow-Up to Pemgarda mAb Could Rival COVID Vaccines

on

Merck Wins FDA Approval for RSV Antibody Drug, Intensifying Market Competition

on

Galderma's Nemluvio Secures Dual EU Approvals for Atopic Dermatitis and Prurigo Nodularis

on